Business Context and Reporting Period
Evgo Inc. filed a Form 8-K dated August 1, 2023, reporting leadership changes and related governance matters. The filing was signed and submitted on August 2, 2023. It is not a periodic financial report and does not provide operating or financial results for a reporting period.
Key Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, charging-network performance, or other financial metrics.
Material Changes Versus the Prior Comparable Period
- Catherine Zoi notified the board that she would cease serving as Chief Executive Officer and as a director, effective on or about November 9, 2023. She will remain a full-time strategic advisor through December 31, 2023.
- Badar Khan was appointed as CEO effective following Ms. Zoi’s effective departure. He had served on Evgo’s board since May 2022.
- Mr. Khan was removed from the Audit, Nominating and Governance, and Compensation Committees. Peter Anderson became chair of the Compensation Committee.
- Evgo notified Nasdaq that it was not in compliance with the audit committee composition requirement under Nasdaq Listing Rule 5605(c)(2)(A), solely because of a vacancy resulting from the leadership transition.
Compensation, Outlook, and Risks
- Mr. Khan’s employment agreement provides for an annual base salary of $550,000 and a target annual bonus equal to 100% of base salary, with a maximum bonus opportunity of 150% of base salary.
- He is expected to receive a one-time $6.0 million equity grant, split evenly between time-based RSUs and performance-based RSUs. The performance tranches require 20-day volume-weighted average share prices of $6, $8, and $10 by the fifth anniversary of the grant date, subject to continued employment and other conditions.
- He is also expected to receive an additional equity grant valued at $4.0 million, consisting of 60% RSUs and 40% stock options, with the 2023 value prorated for expected employment during the year.
- Mr. Khan may receive severance upon termination without cause or resignation for good reason, including salary, bonus, and health-benefit payments. Change-in-control provisions may provide cash severance equal to 200% of base salary plus target bonus, equity acceleration, and up to 18 months of COBRA premiums.
- Ms. Zoi’s transition agreement provides for specified vesting treatment for incentive units, RSUs, and stock options, as well as eligibility for a 2023 cash bonus determined consistently with the treatment of other senior executives.
- Evgo intends to regain compliance with Nasdaq’s audit committee requirement within the applicable cure period. Failure to restore compliance could create listing-related risks.
- The filing states that Ms. Zoi’s departure was not related to any disagreement with Evgo regarding operations, policies, accounting principles, or internal controls.
Important Facts for Investors to Verify
- Confirm the date on which Mr. Khan formally commenced employment and became CEO.
- Monitor Evgo’s appointment of an additional qualified audit committee member and confirmation that Nasdaq compliance was restored within the cure period.
- Review the full Transition Agreement and Employment Agreement filed as Exhibits 10.1 and 10.2 for vesting, severance, release, and termination conditions.
- Assess the potential dilution and expense associated with the $6.0 million and $4.0 million equity awards.
- Review subsequent periodic filings for updated leadership, committee composition, compensation expense, liquidity, operating performance, and any effect of the transition on strategic execution.